CAS 1256580-46-7
:Alectinib
Descripción:
Alectinib es un fármaco de molécula pequeña utilizado principalmente en el tratamiento del cáncer de pulmón de células no pequeñas (NSCLC) que es positivo para reordenamientos del gen de la quinasa del linfoma anaplásico (ALK). Funciona como un inhibidor selectivo de ALK, interrumpiendo las vías de señalización que promueven el crecimiento y la supervivencia del tumor. Alectinib se caracteriza por su alta potencia y especificidad para ALK, lo que ayuda a minimizar los efectos fuera del objetivo y mejora su eficacia terapéutica. El compuesto se administra típicamente por vía oral y tiene un perfil farmacocinético favorable, que incluye buena absorción y una larga vida media, lo que permite una dosificación una o dos veces al día. Su estructura química incluye un núcleo bicíclico, lo que contribuye a su capacidad para penetrar la barrera hematoencefálica, haciéndolo efectivo contra las metástasis cerebrales asociadas con NSCLC positivo para ALK. Los efectos secundarios comunes pueden incluir fatiga, estreñimiento y elevaciones de enzimas hepáticas, lo que requiere monitoreo durante el tratamiento. En general, Alectinib representa un avance significativo en la terapia dirigida contra el cáncer, ofreciendo mejores resultados para los pacientes con perfiles genéticos específicos.
Fórmula:C30H34N4O2
InChI:InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3
Clave InChI:InChIKey=KDGFLJKFZUIJMX-UHFFFAOYSA-N
SMILES:O=C1C2=C(C(C)(C)C=3C1=CC(CC)=C(C3)N4CCC(CC4)N5CCOCC5)NC=6C2=CC=C(C#N)C6
Sinónimos:- 5H-Benzo[b]carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-
- 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
- Af 802
- Alecensa free base
- Ch 5424802
- Ch 542480210
- Rg 7853
- Rg7853
- Alectinib
- Alectinib (CH5424802)
- AF-802,RG-7853
- CH5424802
- CH5424802-alectinib
- 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile Alectinib (CH5424802)
- Ver más sinónimos
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Encontrado 10 productos.
9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile
CAS:Fórmula:C30H34N4O2Pureza:98%Forma y color:SolidPeso molecular:482.6166Alectinib
CAS:Alectinib (RG-7853) is an ALK inhibitor that is selective, orally active, and ATP-competitive. Alectinib has antitumor activity. Cost-effective and quality-assured.Fórmula:C30H34N4O2Pureza:98% - 99.38%Forma y color:SolidPeso molecular:482.62Alectinib
CAS:<p>Alectinib is a drug that inhibits the activity of tyrosine kinases, including ALK, ROS1, and MET. It binds to ATP-binding sites in the active site of these enzymes and prevents them from transferring phosphate groups onto their substrates. Alectinib also inhibits the activity of polymerase chain reaction (PCR) in vitro by binding to DNA. This drug has been shown to inhibit the growth of lymphoma cells in mice by inhibiting protein synthesis and inducing apoptosis. Alectinib also acts as a p-glycoprotein (Pgp) inhibitor, which may be due to its ability to inhibit an alkaline phosphatase.</p>Fórmula:C30H34N4O2Pureza:Min. 98 Area-%Forma y color:White PowderPeso molecular:482.62 g/molCH5424802
CAS:Producto controlado<p>Applications CH5424802 is a highly selective and potent anaplastic lymphoma kinase (ALK) inhibitor capable of blocking the resistant gatekeeper mutant, which results in reduced cell growth. CH5424802 have been clinically evaluated for the treatment of patients with ALK-driven tumors. Potent ALK inhibitor<br>References Sakamoto, H., et al.: Cancer Cell., 19, 679 (2011); Kinoshita, K., et al.: Bio-org. Medn., 20, 1271 (2012);<br></p>Fórmula:C30H34N4O2Forma y color:NeatPeso molecular:482.62CH5424802-d8
CAS:Producto controlado<p>Applications CH5424802-d8 is the labelled form of CH5424802 (C183360). CH5424802 is a highly selective and potent anaplastic lymphoma kinase (ALK) inhibitor capable of blocking the resistant gatekeeper mutant, which results in reduced cell growth. CH5424802 have been clinically evaluated for the treatment of patients with ALK-driven tumors.<br>References Sakamoto, H., et al.: Cancer Cell., 19, 679 (2011); Kinoshita, K., et al.: Bio-org. Medn., 20, 1271 (2012)<br></p>Fórmula:C30H26D8N4O2Forma y color:NeatPeso molecular:490.67





